Get the Stockscreener App
15.00
0.99%
-0.15
Capricor Therapeutics Inc stock is traded at $15.00, with a volume of 1.24M.
It is down -0.99% in the last 24 hours and up +6.69% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$15.15
Open:
$15.29
24h Volume:
1.24M
Relative Volume:
1.08
Market Cap:
$682.05M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-18.07
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-5.96%
1M Performance:
+6.69%
6M Performance:
+227.51%
1Y Performance:
+288.60%
1-Day Range:
$14.75
$15.58
1-Week Range:
$14.28
$16.46
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
15.00 | 682.05M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell? - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2%Still a Buy? - MarketBeat
Capricor Therapeutics Inc (CAPR) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Examining the Potential Price Growth of Capricor Therapeutics Inc (CAPR) - Knox Daily
Capricor Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Capricor Therapeutics Announces Upcoming Participation in Key Investor Conferences for 2025 - Nasdaq
Capricor (CAPR) to Showcase DMD Breakthrough at Three Elite Healthcare Conferences - StockTitan
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.1%Should You Sell? - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by SG Americas Securities LLC - Defense World
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Gaining Ground: Capricor Therapeutics Inc (CAPR) Closes Lower at 14.33, Down -4.91 - The Dwinnex
BlackRock, Inc. Expands Stake in Capricor Therapeutics Inc - GuruFocus.com
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Exosome Diagnostics & Therapeutics Market to Grow by USD 1.01 Billion (2025-2029) with Rising Research in Exosome Therapeutics Boosting the Market, Report on How AI is Driving Market TransformationTechnavio - The Malaysian Reserve
Capricor Therapeutics Inc [CAPR] Stock bought by Insider Nippon Shinyaku Co Ltd for $15.0 million - Knox Daily
Ready to Jump After Recent Trade: Capricor Therapeutics Inc (CAPR) - SETE News
Capricor wins key EU designations for the lead asset - MSN
Capricor Therapeutics Inc (NASDAQ:CAPR) Decline -1.05%, More Rally Possible - Marketing Sentinel
How to Take Advantage of moves in (CAPR) - Stock Traders Daily
5 DMD Candidates to Watch in 2025 - BioSpace
JPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
JPMorgan Chase & Co. Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Equities Analysts Set Expectations for CAPR FY2025 Earnings - Defense World
Analysts Set Expectations for CAPR FY2025 Earnings - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Now Is The Time To Build A Position In Capricor Therapeutics Inc (NASDAQ:CAPR) - Marketing Sentinel
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):